Lexicon Pharmaceuticals (LXRX) Cash from Operations (2010 - 2026)
Lexicon Pharmaceuticals (LXRX) reported Cash from Operations of 14730000.0 for Q1 2026, up 66.35% year-over-year from 8854666.47 in Q1 2025, and up 14.52% quarter-over-quarter from 17233000.0 in Q4 2025.
Lexicon Pharmaceuticals (LXRX) Cash from Operations (2010 - 2026) Analysis & Trends
Lexicon Pharmaceuticals (LXRX) has 17 years of Cash from Operations data on file, last reported at 14730000.0 in Q1 2026.
- Cash from Operations for Q1 2026 came in at 14730000.0, up 66.35% year-over-year; the trailing twelve-month figure through Mar 2026 was 38803000.0 (up 76.82% YoY), and the FY2025 annual result was 67851000.0, up 62.05% from the prior year.
- Cash from Operations advanced to 14730000.0 in Q1 2026 per LXRX's latest filing, from 17233000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 16993000.0 in Q2 2025 and troughed at 55130000.0 in Q1 2024.
- A 5-year average of 30124058.82 and a median of 24422000.0 in 2022 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2023 and 2025: Cash from Operations slumped 134.35% in 2023, then soared 135.01% in 2025.
- A 5-year view of Cash from Operations shows it stood at 21569000.0 in 2022, then plunged by 134.35% to 50548000.0 in 2023, then surged by 57.48% to 21491000.0 in 2024, then climbed by 19.81% to 17233000.0 in 2025, then increased by 14.52% to 14730000.0 in 2026.
- Business Quant data shows LXRX's Cash from Operations at 14730000.0 in Q1 2026, 17233000.0 in Q4 2025, and 23833000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -2.49 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.43 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Lexicon Pharmaceuticals | 804.48 Mn | 633.82 Mn | 20.99 Mn | -14.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -14.73 Mn |
| Mar 31, 2026 | -14.73 Mn |
| Dec 31, 2025 | -17.23 Mn |
| Dec 31, 2025 | -17.23 Mn |
| Sep 30, 2025 | -23.83 Mn |
| Sep 30, 2025 | -23.83 Mn |
| Jun 30, 2025 | 16.99 Mn |
| Jun 30, 2025 | 16.99 Mn |
| Mar 31, 2025 | -43.78 Mn |
| Mar 31, 2025 | -43.78 Mn |
| Dec 31, 2024 | -21.49 Mn |
| Dec 31, 2024 | -21.49 Mn |
| Sep 30, 2024 | -53.62 Mn |
| Sep 30, 2024 | -53.62 Mn |
| Jun 30, 2024 | -48.54 Mn |
| Jun 30, 2024 | -48.54 Mn |
| Mar 31, 2024 | -55.13 Mn |
| Mar 31, 2024 | -55.13 Mn |
| Dec 31, 2023 | -50.55 Mn |
| Dec 31, 2023 | -50.55 Mn |